These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28419094)

  • 1. An open source pharma roadmap.
    Balasegaram M; Kolb P; McKew J; Menon J; Olliaro P; Sablinski T; Thomas Z; Todd MH; Torreele E; Wilbanks J
    PLoS Med; 2017 Apr; 14(4):e1002276. PubMed ID: 28419094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competition: Unlikely partnerships.
    Savage N
    Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
    [No Abstract]   [Full Text] [Related]  

  • 3. Q&A: Bernard Munos.
    Bender E
    Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
    [No Abstract]   [Full Text] [Related]  

  • 4. China spurs pharma innovation.
    Hughes B
    Nat Rev Drug Discov; 2010 Aug; 9(8):581-2. PubMed ID: 20671751
    [No Abstract]   [Full Text] [Related]  

  • 5. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busting the billion-dollar myth: how to slash the cost of drug development.
    Maxmen A
    Nature; 2016 Aug; 536(7617):388-90. PubMed ID: 27558048
    [No Abstract]   [Full Text] [Related]  

  • 7. Increase in R&D openness to tackle disease in the developing world.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2237. PubMed ID: 23234547
    [No Abstract]   [Full Text] [Related]  

  • 8. Bailing out.
    Petsko GA
    Genome Biol; 2011 Oct; 12(10):131. PubMed ID: 22035635
    [No Abstract]   [Full Text] [Related]  

  • 9. Precompetitive consortia in biomedicine--how are we doing?
    Mittleman B; Neil G; Cutcher-Gershenfeld J
    Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 11. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
    Palmer M; Chaguturu R
    Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug development risk and the cost of capital.
    Baras AI; Baras AS; Schulman KA
    Nat Rev Drug Discov; 2012 Apr; 11(5):347-8. PubMed ID: 22498751
    [No Abstract]   [Full Text] [Related]  

  • 13. Future pharmaceutical research: the need to look beyond science.
    Seeger S
    Future Med Chem; 2014 May; 6(7):721-3. PubMed ID: 24941866
    [No Abstract]   [Full Text] [Related]  

  • 14. Ask the experts: the challenges and benefits of flow chemistry to optimize drug development.
    Anderson N; Gernaey KV; Jamison TF; Kircher M; Wiles C; Leadbeater NE; Sandford G; Richardson P
    Future Med Chem; 2012 Sep; 4(14):1779-89. PubMed ID: 23043475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An audience with... Victoria G. Hale.
    Hale VG
    Nat Rev Drug Discov; 2005 Nov; 4(11):878. PubMed ID: 16299916
    [No Abstract]   [Full Text] [Related]  

  • 16. Vertical disintegration: a strategy for pharmaceutical businesses in 2009?
    Dixon J; Lawton G; Machin P
    Nat Rev Drug Discov; 2009 Jun; 8(6):435. PubMed ID: 19483701
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 18. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
    Wood J; Sames L; Moore A; Ekins S
    Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the most important approach in current drug discovery: doing the right things or doing things right?
    Elebring T; Gill A; Plowright AT
    Drug Discov Today; 2012 Nov; 17(21-22):1166-9. PubMed ID: 22569181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. News & Analysis: new initiative aims to improve success of early stage drug discovery.
    Coaker H
    Future Med Chem; 2014 May; 6(7):733. PubMed ID: 24941869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.